Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LW 231

Next Previous
Drug Profile

LW 231

Alternative Names: LW-231

Latest Information Update: 23 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Longwood Biopharma
  • Class Antivirals; Small molecules
  • Mechanism of Action CGAS protein modulators; Nucleocapsid protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 18 Sep 2025 Longwood Biopharma plans a phase I/II trial for Hepatitis B (Treatment-naive) in China (PO, Tablet) (NCT07179575)
  • 04 Jan 2024 LW 231 is available for licensing as of 04 Jan 2024. https://www.lwbpsh.com/en/research (Longwood Biopharma website, January 2024)
  • 16 Nov 2023 Longwood Biopharma completes a phase-I trial in Hepatitis B in China (PO) (CTR20221609)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top